{{Rsnum
|rsid=1954787
|Gene=GRIK4
|Chromosome=11
|position=120792654
|Orientation=plus
|GMAF=0.4679
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=GRIK4
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 23.9 | 54.9 | 21.2
| HCB | 61.5 | 33.3 | 5.2
| JPT | 88.5 | 11.5 | 0.0
| YRI | 0.7 | 11.6 | 87.8
| ASW | 3.5 | 29.8 | 66.7
| CHB | 61.5 | 33.3 | 5.2
| CHD | 64.2 | 33.0 | 2.8
| GIH | 26.7 | 47.5 | 25.7
| LWK | 3.6 | 19.1 | 77.3
| MEX | 43.1 | 43.1 | 13.8
| MKK | 6.4 | 33.3 | 60.3
| TSI | 28.4 | 51.0 | 20.6
| HapMapRevision=28
}}
[[rs1954787]], located in an intron of the [[GRIK4]] gene, was found to be associated with a somewhat increased rate of successful response to treatment of [[depression]] with the drug [[citalopram]]. {{PMID|17671280}}

From the abstract of this article:

"The effect size of (this) [[GRIK4]] marker alone was modest, but homozygote carriers of the treatment-response-associated marker alleles of both the [[GRIK4]] and [[HTR2A]] (see [[rs7997012]]) genes were 23% less likely to experience nonresponse to ([[citalopram]]) treatment relative to participants who did not carry any of these marker alleles."

* See also [http://www.anxietyinsights.info/antipressant_effectiveness_predicted_by_gene_variation.htm Anxiety Blog] posting

{{PMID Auto
|PMID=19924111
|Title=Polymorphisms in GRIK4, HTR2A, and FKBP5 Show Interactive Effects in Predicting Remission to Antidepressant Treatment
|OA=1
}}

{{PharmGKB
|RSID=rs1954787
|Name_s=
|Gene_s=GRIK4
|Feature=
|Evidence=PubMed ID:17671280
|Annotation=A study in 1,816 eligible patients from the STAR*D cohort found that genetic variation in a kainic acid-type glutamate receptor is reproducibly associated with response to the antidepressant citalopram.
|Drugs=citalopram
|Drug Classes=
|Diseases=Depression
|Curation Level=Curated
|PharmGKB Accession ID=PA162316593
}}

{{PMID Auto
|PMID=21172166
|Title=Pharmacogenetics of antidepressant response.
|OA=1
}}

{{PMID Auto
|PMID=21208417
|Title=International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1954787
|overall_frequency_n=48
|overall_frequency_d=128
|overall_frequency=0.375
|n_genomes=29
|n_genomes_annotated=0
|n_haplomes=39
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23394390
|Title=Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}
{{on chip | NatGeo2}}